All In Biotech

Drug Trial Radar · NCT06077331

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of HS-10374 in Adult Subjects With Moderate To Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Dec 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

120

Planned (sponsor's estimate)

Start

Sep 28, 2023

Primary completion

Jul 31, 2024

Study completion Aug 31, 2024

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Oct 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.

Conditions

  • Psoriasis

Interventions

  • HS-10374 tablets 1mgDrug

    Administered orally QD for 12 weeks

  • HS-10374 tablets 5mgDrug

    Administered orally QD for 12 weeks

  • HS-10374-matched placebo tabletsDrug

    Administered orally QD for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with moderate to severe plaque psoriasis achieving PASI 75 response at Week 12Time frame: Baseline to Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital of Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.